Navigation Links
Progress toward an antitumor vaccine

How can we induce the body to use its own weapon, the immune system, to battle cancer" In principle, by the same means used against infectious diseases: immunization. The production of a selective vaccine is not a trivial task, however. A team led by Horst Kunst at the University of Mainz has now found a way to bind a molecule that is typical for tumors to a carrier protein without irritating the immune system. As they report in the journal Angewandte Chemie, their method is based on an immunocompatible connection by way of a sulfur atom, namely, a thioether.

Epithelial tumor cells have unusually large amounts of mucin MUC1 on their surface. This MUC1, in comparison with its “normal” cousins, is also modified in a very characteristic manner. Mucins are mucilaginous substances that protect the surfaces of mucus membranes. They are glycoproteins—macromolecules with a central protein chain and long side chains made of polysaccharides. The modified MUC1 would be a good target molecule (antigen) for antibodies in immunological antitumor therapy.

The difficulty with this approach is that such sugar-containing compounds are completely ineffective at stimulating the immune system to form antibodies. “Immunization is only successful if the vaccine is anchored to an immunizing carrier protein by means of a spacer,” explains Kunz. This would be very easy to accomplish with polysaccharides, but turns out to be very complicated with glycoproteins, because the protein portion of the molecule has many reactive groups that are attacked in the coupling reaction. “In addition,” says Kunz, “many of the structures that make suitable anchors are themselves highly immunogenic, which can suppress the immune response against the true target, the glycoprotein.”

This team has now found a good anchoring technique: Their anchor is a thioether (two carbon atoms coupled together through a sulfur atom). To this end, the carrier protein is first equipped with a spac er, which has an allyl group (two carbon atoms attached by a double bond) at its end. The glycopeptide is coupled to a building block that causes thiols (sulfur–hydrogen groups) to protrude from the molecule. In the next, light-initiated (photochemical) reaction, only the desired thioether bonds are formed—no side reactions occur at other locations in the peptide chain.

“Synthetic glycopeptide antigens containing structural elements typical of tumors in the sugar as well as the protein segment,” explains Kunz, “can thus be attached to the carrier protein in a controlled fashion. The largely nonimmunogenic thioether bridges could clear the way for the development of vaccines for immunization against tumor cells.”


'"/>

Source:John Wiley & Sons, Inc.


Related biology news :

1. Bevacizumab Combined With Chemotherapy Improves Progression-Free Survival for Patients With Advanced Breast Cancer
2. AIDS Public Awareness Campaign Expands Following Report Of Rapidly Progressive HIV
3. Progress on HIV/AIDS significant but insufficient
4. Progress being made in exploring potential use of stem cells to treat heart disease
5. Progress made in HIV vaccine development
6. Progress toward artificial photosynthesis?
7. Unchecked DNA replication drives earliest steps toward cancer
8. Virologists make major step towards understanding the process of HIV infection
9. Moffitt-USF head toward first human trials of anti-cancer drug that targets protein AKT
10. Cats indifference towards sugar explained
11. A step toward the $1,000 personal genome using readily available lab equipment

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the ... at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application ... team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
Breaking Biology Technology: